Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Rating) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 359,100 shares, an increase of 49.8% from the April 15th total of 239,700 shares. Based on an average daily volume of 521,900 shares, the days-to-cover ratio is presently 0.7 days. Currently, 5.2% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Aegis assumed coverage on Avenue Therapeutics in a research note on Monday, April 3rd. They set a “buy” rating and a $32.00 target price for the company.

Avenue Therapeutics Trading Down 1.0 %

Shares of NASDAQ ATXI opened at $1.03 on Friday. Avenue Therapeutics has a twelve month low of $0.87 and a twelve month high of $16.65. The stock has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.34. The stock has a market cap of $8.16 million, a P/E ratio of -0.58 and a beta of -0.43.

Institutional Investors Weigh In On Avenue Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATXI. Virtu Financial LLC purchased a new stake in Avenue Therapeutics in the first quarter valued at approximately $28,000. Renaissance Technologies LLC purchased a new stake in Avenue Therapeutics in the second quarter valued at approximately $34,000. Citadel Advisors LLC purchased a new stake in shares of Avenue Therapeutics during the third quarter worth approximately $362,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Avenue Therapeutics during the third quarter worth approximately $145,000. Hedge funds and other institutional investors own 11.85% of the company’s stock.

Avenue Therapeutics Company Profile

(Get Rating)

Avenue Therapeutics, Inc is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain.